San Diego’s TargeGen, a biotechnology targeting disease treatments related to abnormal blood-vessel growth, raised $40 million in a fourth funding round. New investors included Innovis Investments, VantagePoint Venture Partners and CTI Life Sciences Fund, joined by existing investors Forward Ventures, Enterprise Partners, Chicago Growth Partners.
TargeGen’s potential disease targets range from eye diseases such as age-related macular degeneration (AMD) to cancer to heart disease. Its leading drug candidate, TG100801, completed an early-stage phase I trial in AMD-related vision loss in February, but said only that the drug appeared safe and “well tolerated.”
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.
